Duramed (DRMD) Synthetic Estrogen Product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andy Blaher who wrote (1666)	6/21/2000 4:34:00 PM
From: vestor	Read Replies (1) of 1837

It appears to be a valuation move. When you consider all the expense that was one time and the operating expense that has been moved to Solvay and also factor in recent drug approvals and the cuurent share price I think investors see improvement in earnings going forward. The baby boomer demographics bode well for drug companies. The number of drug companys has dropped from just a decade ago.... There are about 100 of substance. Also patents are expiring in droves. great opportunity for generic drug makers. Lets hope that DRMD manages well given the environment is so positive.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next